Emergent Biosolutions, Inc. (EBS) financial statements (2022 and earlier)
Company profile
| Business Address |
400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG, MD 20879 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 576 | 621 | 168 | 112 | 178 | 272 | 313 | ||
| Cash and cash equivalents | 576 | 621 | 168 | 112 | 178 | 272 | 313 | ||
| Restricted cash and investments | 0 | 0 | 0 | 0 | 1 | ||||
| Receivables | 275 | 231 | 275 | 271 | 146 | 148 | 127 | ||
| Inventory, net of allowances, customer advances and progress billings | 351 | 307 | 223 | 206 | 143 | 74 | 77 | ||
| Inventory | 351 | 307 | 223 | 206 | 143 | 74 | 77 | ||
| Contract with customer, asset | 22 | ✕ | ✕ | ✕ | |||||
| Deferred costs | 1 | ||||||||
| Other undisclosed current assets | 49 | 37 | 20 | 30 | 17 | 16 | 22 | ||
| Total current assets: | 1,272 | 1,196 | 686 | 621 | 485 | 510 | 539 | ||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 800 | 644 | 542 | 510 | 407 | 376 | 332 | ||
| Intangible assets, net (including goodwill) | 830 | 930 | 980 | 1,021 | 169 | 75 | 112 | ||
| Goodwill | 225 | 267 | 267 | 260 | 49 | 41 | 55 | ||
| Intangible assets, net (excluding goodwill) | 605 | 663 | 713 | 762 | 120 | 34 | 57 | ||
| Other noncurrent assets | 57 | 113 | 77 | 14 | 6 | 2 | 7 | ||
| Other undisclosed noncurrent assets | 42 | 63 | 3 | 6 | 54 | ||||
| Total noncurrent assets: | 1,687 | 1,687 | 1,641 | 1,609 | 585 | 460 | 505 | ||
| TOTAL ASSETS: | 2,959 | 2,883 | 2,327 | 2,229 | 1,070 | 970 | 1,044 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 269 | 268 | 197 | 174 | 84 | 76 | 87 | ||
| Accounts payable | 129 | 136 | 95 | 81 | 42 | 35 | 46 | ||
| Accrued liabilities | 52 | 47 | 40 | 31 | 5 | 6 | 6 | ||
| Employee-related liabilities | 89 | 85 | 62 | 58 | 38 | 35 | 35 | ||
| Taxes payable | 5 | ||||||||
| Debt | 13 | 10 | 20 | ||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | 13 | 7 | 8 | ||
| Contract with customer, liability | ✕ | ✕ | ✕ | 11 | ✕ | ✕ | ✕ | ||
| Other liabilities | 73 | 83 | 4 | ||||||
| Other undisclosed current liabilities | 32 | 34 | 3 | 6 | 2 | 3 | 5 | ||
| Total current liabilities: | 374 | 385 | 216 | 200 | 100 | 106 | 100 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 809 | 841 | 798 | 785 | 13 | 248 | 253 | ||
| Long-term debt, excluding current maturities | 809 | 841 | 798 | 785 | 13 | 248 | 253 | ||
| Liabilities, other than long-term debt | 157 | 211 | 134 | 179 | 34 | 10 | 8 | ||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | 17 | 8 | 7 | ||
| Accounts payable and accrued liabilities | 11 | 13 | |||||||
| Deferred revenue | 5 | 56 | ✕ | ✕ | ✕ | ✕ | |||
| Contract with customer, liability | ✕ | ✕ | 86 | 63 | ✕ | ✕ | ✕ | ||
| Deferred tax liabilities, net | ✕ | ✕ | ✕ | 68 | |||||
| Deferred income tax liabilities | 95 | 53 | ✕ | ✕ | ✕ | ✕ | |||
| Other liabilities | 53 | 68 | 49 | 38 | 5 | 2 | 1 | ||
| Business combination, contingent consideration, liability | 5 | 34 | |||||||
| Other undisclosed noncurrent liabilities | 90 | 54 | 10 | 10 | 23 | ||||
| Total noncurrent liabilities: | 966 | 1,052 | 1,023 | 1,018 | 58 | 268 | 284 | ||
| Total liabilities: | 1,340 | 1,436 | 1,239 | 1,219 | 158 | 374 | 384 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 1,619 | 1,447 | 1,089 | 1,011 | 912 | 596 | 660 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Treasury stock, value | (152) | (40) | (40) | (40) | (39) | (6) | (6) | ||
| Additional paid in capital | 829 | 785 | 716 | 689 | 618 | 352 | 318 | ||
| Accumulated other comprehensive loss | (16) | (25) | (10) | (6) | (4) | (4) | (3) | ||
| Retained earnings | 958 | 727 | 422 | 367 | 337 | 254 | 351 | ||
| Total stockholders' equity: | 1,619 | 1,447 | 1,089 | 1,011 | 912 | 596 | 660 | ||
| TOTAL LIABILITIES AND EQUITY: | 2,959 | 2,883 | 2,327 | 2,229 | 1,070 | 970 | 1,044 | ||
Income statement (P&L) ($ in millions)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 1,793 | 1,555 | 1,106 | 782 | 561 | 489 | 523 | |
| Revenue, net | ✕ | ✕ | ✕ | ✕ | 561 | 489 | 523 | |
| Cost of revenue (Cost of Goods and Services Sold) | (524) | (434) | (322) | (196) | (131) | (124) | ||
| Gross profit: | 1,793 | 1,031 | 673 | 460 | 365 | 357 | 398 | |
| Operating expenses | (1,440) | (1,122) | (992) | (241) | (252) | (302) | ||
| Other undisclosed operating income (loss) | 524 | 434 | (370) | |||||
| Operating income: | 353 | 434 | 114 | 90 | 124 | 106 | 96 | |
| Nonoperating expense | (38) | (27) | (37) | (8) | (6) | (6) | (6) | |
| Investment income, nonoperating | 2 | 1 | 1 | |||||
| Other nonoperating income (expense) | (4) | 5 | 2 | 2 | (1) | 0 | (0) | |
| Interest and debt expense | (35) | (31) | (38) | (10) | (7) | (8) | (7) | |
| Other undisclosed income from continuing operations before equity method investments, income taxes | 31 | 38 | 10 | 7 | 8 | 7 | ||
| Income from continuing operations before equity method investments, income taxes: | 280 | 407 | 77 | 82 | 119 | 99 | 90 | |
| Other undisclosed income from continuing operations before income taxes | 35 | |||||||
| Income from continuing operations before income taxes: | 314 | 407 | 77 | 82 | 119 | 99 | 90 | |
| Income tax expense | (84) | (102) | (23) | (19) | (36) | (37) | (27) | |
| Income from continuing operations: | 231 | 305 | 55 | 63 | 83 | 63 | 63 | |
| Loss from discontinued operations | (11) | |||||||
| Net income available to common stockholders, basic: | 231 | 305 | 55 | 63 | 83 | 52 | 63 | |
| Interest on convertible debt | 3 | 3 | ||||||
| Net income available to common stockholders, diluted: | 231 | 305 | 55 | 63 | 83 | 55 | 66 | |
Comprehensive Income ($ in millions)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net income: | 231 | 305 | 55 | 63 | 83 | 52 | 63 | |
| Other comprehensive loss | (0) | (2) | ||||||
| Other undisclosed comprehensive income (loss) | 1 | (2) | 0 | |||||
| Comprehensive income: | 231 | 305 | 54 | 61 | 83 | 50 | 63 | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 9 | (15) | (4) | |||||
| Comprehensive income, net of tax, attributable to parent: | 240 | 290 | 50 | 61 | 83 | 50 | 63 | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.